中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Menu
Volume 37 Issue 1
Jan.  2021
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Clinical Hepatology  > 2021  >  37(1): 188-191

The role and mechanism of invariant natural killer T cells in liver anti-tumor immunity

DOI: 10.3969/j.issn.1001-5256.2021.01.041

  • Department of Hepatopathy and Cancer Biotherapy, Beijing YouAn Hospital, Capital Medical University, Beijing 100069, China

  • Received Date: 2020-05-20
  • Accepted Date: 2020-08-31
  • Published Date: 2021-01-20
    Abstract
  • Invariant natural killer T (iNKT) cells are a T lymphocyte subset derived from the thymus and can express both natural killer cell-related receptors and T cell receptor. The iNKT cells are widely distributed in the body and are enriched in the liver, and they exhibit unique functional characteristics and can secrete cytokines and regulate the activity of other immune cells in microenvironment, so as to achieve the role of immune surveillance and disease prevention; especially in tumor microenvironment, iNKT cells can stimulate anti-tumor immune response and reverse immunosuppressive microenvironment in the liver. This article reviews the biological characteristics of iNKT cells and their special role in liver immune homeostasis, especially the anti-tumor effect and mechanism of iNKT cells.

     

    • FullText(HTML)
    • References(43)
  • [1]
    BENDELAC A, SAVAGE PB, TEYTON L. The biology of NKT cells[J]. Annu Rev Immunol, 2007, 25: 297-336. DOI: 10.1146/annurev.immunol.25.022106.141711
    [2]
    ZHANG Y, SPRINGFIELD R, CHEN S, et al. Alpha-galcer and iNKT cell-based cancer immunotherapy: Realizing the therapeutic potentials[J]. Front Immunol, 2019, 10: 1126. DOI: 10.3389/fimmu.2019.01126
    [3]
    BROSSAY L, CHIODA M, BURDIN N, et al. CD1d-mediated recognition of an alpha-galactosylceramide by natural killer T cells is highly conserved through mammalian evolution[J]. J Exp Med, 1998, 188(8): 1521-1528. DOI: 10.1084/jem.188.8.1521
    [4]
    MORENO M, MOL BM, von MENSDORFF-POUILLY S, et al. Differential indirect activation of human invariant natural killer T cells by Toll-like receptor agonists[J]. Immunotherapy, 2009, 1(4): 557-570.
    [5]
    KITAMURA H, IWAKABE K, YAHATA T, et al. The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells[J]. J Exp Med, 1999, 189(7): 1121-1128. DOI: 10.1084/jem.189.7.1121
    [6]
    NAIR S, DHODAPKAR MV. Natural killer T cells in cancer immunotherapy[J]. Front Immunol, 2017, 8: 1178. DOI: 10.3389/fimmu.2017.01178
    [7]
    GANSUVD B, HAGIHARA M, YU Y, et al. Human umbilical cord blood NK T cells kill tumors by multiple cytotoxic mechanisms[J]. Hum Immunol, 2002, 63(3): 164-175. DOI: 10.1016/S0198-8859(01)00382-2
    [8]
    CAMERON G, GODFREY DI. Differential surface phenotype and context-dependent reactivity of functionally diverse NKT cells[J]. Immunol Cell Biol, 2018.[Online ahead of print]
    [9]
    EBERL G, LEES R, SMILEY ST, et al. Tissue-specific segregation of CD1d-dependent and CD1d-independent NK T cells[J]. J Immunol, 1999, 162(11): 6410-6419.
    [10]
    LEE YJ, WANG H, STARRETT GJ, et al. Tissue-specific distribution of iNKT cells impacts their cytokine response[J]. Immunity, 2015, 43(3): 566-578. DOI: 10.1016/j.immuni.2015.06.025
    [11]
    KIM CH, JOHNSTON B, BUTCHER EC. Trafficking machinery of NKT cells: Shared and differential chemokine receptor expression among V alpha 24(+)V beta 11(+) NKT cell subsets with distinct cytokine-producing capacity[J]. Blood, 2002, 100(1): 11-16. DOI: 10.1182/blood-2001-12-0196
    [12]
    JOHNSTON B, KIM CH, SOLER D, et al. Differential chemokine responses and homing patterns of murine TCR alpha beta NKT cell subsets[J]. J Immunol, 2003, 171(6): 2960-2969. DOI: 10.4049/jimmunol.171.6.2960
    [13]
    THOMAS SY, HOU R, BOYSON JE, et al. CD1d-restricted NKT cells express a chemokine receptor profile indicative of Th1-type inflammatory homing cells[J]. J Immunol, 2003, 171(5): 2571-2580. DOI: 10.4049/jimmunol.171.5.2571
    [14]
    BANDYOPADHYAY K, MARRERO I, KUMAR V. NKT cell subsets as key participants in liver physiology and pathology[J]. Cell Mol Immunol, 2016, 13(3): 337-346. DOI: 10.1038/cmi.2015.115
    [15]
    RACANELLI V, REHERMANN B. The liver as an immunological organ[J]. Hepatology, 2006, 43(2 Suppl 1): s54-s62.
    [16]
    WISSE E. An electron microscopic study of the fenestrated endothelial lining of rat liver sinusoids[J]. J Ultrastruct Res, 1970, 31(1): 125-150.
    [17]
    GEISSMANN F, CAMERON TO, SIDOBRE S, et al. Intravascular immune surveillance by CXCR6+ NKT cells patrolling liver sinusoids[J]. PLoS Biol, 2005, 3(4): e113. DOI: 10.1371/journal.pbio.0030113
    [18]
    KEE JY, ITO A, HOJO S, et al. Chemokine CXCL16 suppresses liver metastasis of colorectal cancer via augmentation of tumor-infiltrating natural killer T cells in a murine model[J]. Oncol Rep, 2013, 29(3): 975-982. DOI: 10.3892/or.2012.2185
    [19]
    KUBES P, JENNE C. Immune responses in the liver[J]. Annu Rev Immunol, 2018, 36: 247-277. DOI: 10.1146/annurev-immunol-051116-052415
    [20]
    JACOB AI, GOLDBERG PK, BLOOM N, et al. Endotoxin and bacteria in portal blood[J]. Gastroenterology, 1977, 72(6): 1268-1270. DOI: 10.1016/S0016-5085(77)80025-5
    [21]
    DOHERTY DG. Immunity, tolerance and autoimmunity in the liver: A comprehensive review[J]. J Autoimmun, 2016, 66: 60-75. DOI: 10.1016/j.jaut.2015.08.020
    [22]
    SINGH AK, GAUR P, DAS SN. Natural killer T cell anergy, co-stimulatory molecules and immunotherapeutic interventions[J]. Hum Immunol, 2014, 75(3): 250-260. DOI: 10.1016/j.humimm.2013.12.004
    [23]
    JIANG X, SHIMAOKA T, KOJO S, et al. Cutting edge: Critical role of CXCL16/CXCR6 in NKT cell trafficking in allograft tolerance[J]. J Immunol, 2005, 175(4): 2051-2055. DOI: 10.4049/jimmunol.175.4.2051
    [24]
    HUANG W, HE W, SHI X, et al. The role of CD1d and MR1 restricted T cells in the liver[J]. Front Immunol, 2018, 9: 2424. DOI: 10.3389/fimmu.2018.02424
    [25]
    KANEKO Y, HARADA M, KAWANO T, et al. Augmentation of Valpha14 NKT cell-mediated cytotoxicity by interleukin 4 in an autocrine mechanism resulting in the development of concanavalin A-induced hepatitis[J]. J Exp Med, 2000, 191(1): 105-114. DOI: 10.1084/jem.191.1.105
    [26]
    ZHU S, ZHANG H, BAI L. NKT cells in liver diseases[J]. Front Med, 2018, 12(3): 249-261. DOI: 10.1007/s11684-018-0622-3
    [27]
    MARICIC I, SHENG H, MARRERO I, et al. Inhibition of type I natural killer T cells by retinoids or following sulfatide-mediated activation of type Ⅱ natural killer T cells attenuates alcoholic liver disease in mice[J]. Hepatology, 2015, 61(4): 1357-1369. DOI: 10.1002/hep.27632
    [28]
    KAKIMI K, GUIDOTTI LG, KOEZUKA Y, et al. Natural killer T cell activation inhibits hepatitis B virus replication in vivo[J]. J Exp Med, 2000, 192(7): 921-930. DOI: 10.1084/jem.192.7.921
    [29]
    YE L, WANG X, WANG S, et al. CD56+ T cells inhibit hepatitis C virus replication in human hepatocytes[J]. Hepatology, 2009, 49(3): 753-762. DOI: 10.1002/hep.22715
    [30]
    ZAHRAN AM, ABDEL-MEGUID MM, ASHMAWY AM, et al. Frequency and implications of natural killer and natural killer T cells in hepatocellular carcinoma[J]. Egypt J Immunol, 2018, 25(2): 45-52.
    [31]
    KENNA T, GOLDEN-MASON L, PORCELLI SA, et al. NKT cells from normal and tumor-bearing human livers are phenotypically and functionally distinct from murine NKT cells[J]. J Immunol, 2003, 171(4): 1775-1779. DOI: 10.4049/jimmunol.171.4.1775
    [32]
    XIAO YS, GAO Q, XU XN, et al. Combination of intratumoral invariant natural killer T cells and interferon-gamma is associated with prognosis of hepatocellular carcinoma after curative resection[J]. PLoS One, 2013, 8(8): e70345. DOI: 10.1371/journal.pone.0070345
    [33]
    MIYAGI T, TAKEHARA T, TATSUMI T, et al. CD1d-mediated stimulation of natural killer T cells selectively activates hepatic natural killer cells to eliminate experimentally disseminated hepatoma cells in murine liver[J]. Int J Cancer, 2003, 106(1): 81-89. DOI: 10.1002/ijc.11163
    [34]
    YANAGISAWA K, SEINO K, ISHIKAWA Y, et al. Impaired proliferative response of V alpha 24 NKT cells from cancer patients against alpha-galactosylceramide[J]. J Immunol, 2002, 168(12): 6494-6499. DOI: 10.4049/jimmunol.168.12.6494
    [35]
    MARGALIT M, SHIBOLET O, KLEIN A, et al. Suppression of hepatocellular carcinoma by transplantation of ex-vivo immune-modulated NKT lymphocytes[J]. Int J Cancer, 2005, 115(3): 443-449. DOI: 10.1002/ijc.20889
    [36]
    BAE EA, SEO H, KIM IK, et al. Roles of NKT cells in cancer immunotherapy[J]. Arch Pharm Res, 2019, 42(7): 543-548. DOI: 10.1007/s12272-019-01139-8
    [37]
    FU Y, LIU S, ZENG S, et al. From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma[J]. J Exp Clin Cancer Res, 2019, 38(1): 396. DOI: 10.1186/s13046-019-1396-4
    [38]
    GEBREMESKEL S, CLATTENBURG DR, SLAUENWHITE D, et al. Natural killer T cell activation overcomes immunosuppression to enhance clearance of postsurgical breast cancer metastasis in mice[J]. Oncoimmunology, 2015, 4(3): e995562. DOI: 10.1080/2162402X.2014.995562
    [39]
    KO HJ, LEE JM, KIM YJ, et al. Immunosuppressive myeloid-derived suppressor cells can be converted into immunogenic APCs with the help of activated NKT cells: An alternative cell-based antitumor vaccine[J]. J Immunol, 2009, 182(4): 1818-1828. DOI: 10.4049/jimmunol.0802430
    [40]
    HIX LM, SHI YH, BRUTKIEWICZ RR, et al. CD1d-expressing breast cancer cells modulate NKT cell-mediated antitumor immunity in a murine model of breast cancer metastasis[J]. PLoS One, 2011, 6(6): e20702. DOI: 10.1371/journal.pone.0020702
    [41]
    BAE EA, SEO H, KIM BS, et al. Activation of NKT cells in an anti-PD-1-resistant tumor model enhances antitumor immunity by reinvigorating exhausted CD8 T cells[J]. Cancer Res, 2018, 78(18): 5315-5326. DOI: 10.1158/0008-5472.CAN-18-0734
    [42]
    HECZEY A, LIU D, TIAN G, et al. Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy[J]. Blood, 2014, 124(18): 2824-2833. DOI: 10.1182/blood-2013-11-541235
    [43]
    YONG CSM, DARDALHON V, DEVAUD C, et al. CAR T-cell therapy of solid tumors[J]. Immunol Cell Biol, 2017, 95(4): 356-363. DOI: 10.1038/icb.2016.128
    • Relative Articles

  • Relative Articles

    [1]Li Na, Gou Wei, Cui WeiLi. Efficacy of telbivudine combined with adefovir dipivoxil and pegylated interferon combined with entecavir as antiviral therapy for chronic hepatitis B: a comparative analysis[J]. Journal of Clinical Hepatology, 2016, 32(9): 1714-1716. doi: 10.3969/j.issn.1001-5256.2016.09.015
    [2]Yang DongQiang, Chen Fang, Kang Yi, Ding GangQiang, Xiao ErHui, Peng Zhen, Shang Jia. Genotypes and resistance loci in patients with chronic hepatitis B achieving virologic breakthrough in treatment with lamivudine combined with adefovir after developing drug resistance in treatment with lamivudine alone[J]. Journal of Clinical Hepatology, 2016, 32(3): 480-483. doi: 10.3969/j.issn.1001-5256.2016.03.016
    [3]Zhang Wen, Yu JianGuo, Zhu GuiZhong, Zhao ZhanDong, Wang XiaoWei. Clinical efficacy of entecavir combined with adefovir in chronic hepatitis B patients with high viral load[J]. Journal of Clinical Hepatology, 2014, 30(11): 1169-1172. doi: 10.3969/j.issn.1001-5256.2014.11.019
    [4]Huang MeiJin, Tan HouJi, He YanZhuan, Huang QiWen, Zhou YaoNan, Qiu HaiXian. Forty-eight-week efficacy of adefovir dipivoxil alone versus combined with lamivudine in treatment of lamivudine-resistant HBeAg-positive chronic hepatitis B[J]. Journal of Clinical Hepatology, 2014, 30(7): 636-638. doi: 10.3969/j.issn.1001-5256.2014.07.015
    [5]Ruan BingWei, Lu XiaoJu, Lin YanMing, Chen RongCe, Chen XinZhi, Ceng GuangZhong, Liu YanPing. Evaluation of adverse reactions induced by adefovir dipivoxil in 85 chronic hepatitis B patients[J]. Journal of Clinical Hepatology, 2013, 29(2): 104-106.
    [6]Ma YanHong. Clinical effect of initial combination therapy with lamivudine plus adefovir dipivoxil in 48-week treatment of HBeAg-positive chronic hepatitis B[J]. Journal of Clinical Hepatology, 2013, 29(8): 631-632. doi: 10.3969/j.issn.1001-5256.2013.08.020
    [7]Yan HaiMing, Chen JianHua, Ye YiNong, Long Hui, Wang XiangHuai. Clinical effects of lamivudine combined with adefovir dipivoxil and entecavir alone in 48-week treatment of HBeAg-positive chronic hepatitis B:preliminary comparative study[J]. Journal of Clinical Hepatology, 2013, 29(7): 508-511. doi: 1001-5256 (2013) 07-0508-04
    [8]Song MinNing, Huang WenQi, Min Feng, Hong MeiZhu, Fan RongHua, Wu WeiBing, Zhang Li. The efficacy of 3 years adefovir monotherapy in chronic hepatitis B patients with lamivudine resistance[J]. Journal of Clinical Hepatology, 2012, 28(1): 29-32.
    [9]Liu LongGen, Ye ChunYan, Tong XueCheng. Maintenance of negative HBV DNA in patients with chronic hepatitis B during 96 weeks followup with active replacement of Adefovir dipivoxil with Lamivudine[J]. Journal of Clinical Hepatology, 2011, 27(3): 292-294.
    [10]Geng JianZhang, Fan XiaoHong, Lu HaiYing, Li Jing, Tian XiuLan, Xu XiaoYuan. The evaluation of de novo combination of antiviral treatment to hepatitis B patients with decompensated cirrhosis[J]. Journal of Clinical Hepatology, 2011, 27(8): 837-839+843.
    [11]Gu QiangYe, Li Qin, Ge XiuLin. Observation of long-term efficacy of different treatment protocol of Adefovir dipivoxil in chronic hepatitis B patients with Lamivudine-resistance[J]. Journal of Clinical Hepatology, 2011, 27(4): 411-413.
    [12]Song MinNing, Zhang Li, Huang WenQi, Min Feng. Treatment of chronic hepatitis B with Adefovir dipivoxil:A 3 years observation of clinical efficacy and drug resistance[J]. Journal of Clinical Hepatology, 2010, 26(1): 22-24.
    [13]Yang YaFang, Yang XiaoPing, Dong JianGuo, Wang ZhiGang, Liu YanPing, Zhao TieJun, Gao Feng.

    Analysis of short-term efficacy of entecavir and adefovir dipivoxil in the treatment of HBeAg-positive chronic hepatitis B

    [J]. Journal of Clinical Hepatology, 2010, 26(3): 326-327.
    [14]Zhu FeiYan. The clinical effect Adefovir dipivoxil in Lamivudine resistant HBeAg positive chronic hepatitis B patients[J]. Journal of Clinical Hepatology, 2010, 26(5): 517-518.
    [19]Cao TianGao, Li JingNan, Shi YunZhen, Li ChaoXia. The clinical study of foscarnet sodium combined with adefovir dipivoxil for lamivudine-resistant patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2008, 24(4): 248-250.
    • Supplements(0)
    • Cited By

  • Cited by

    Periodical cited type(11)

    1. 肖春桃，李贤秋，甘佩灵，潘潇，周贤. 基于倾向性评分匹配分析门静脉血栓对肝硬化患者预后的影响. 临床肝胆病杂志. 2021(08): 1829-1835 . 本站查看
    2. 王彤，牛焕章，杜廷伟，魏乐群. 乙型肝炎肝硬化患者门静脉血栓发生的影响因素及抗凝治疗效果研究. 深圳中西医结合杂志. 2021(17): 134-136 .
    3. 姜炅，袁佳，史海涛，戴社教. 血清ALT、AST联合NFS评分对非酒精性脂肪性肝硬化患者食管胃底静脉曲张严重程度的评估价值. 中西医结合肝病杂志. 2020(04): 314-317 .
    4. 李英，高磊，胡扬喜，胡德升. 低分子肝素钙联合右旋糖酐在肝硬化门静脉高压症术后静脉血栓形成预防中的应用. 肝脏. 2019(07): 788-790 .
    5. 吕靖，董思思，顾宏图，赵长青，刘成海. 肝硬化并发门静脉血栓的危险因素及中医证候特点. 临床肝胆病杂志. 2019(10): 2210-2213 . 本站查看
    6. 陈仙艳. 肝硬化合并上消化道出血患者门静脉血栓形成危险因素分析与护理. 护理实践与研究. 2019(18): 13-15 .
    7. 牟思玉，杨哲，吴力群，邱轩，郭珈铭. 肝硬化门静脉高压脾切除术后门静脉血栓形成的预测因素分析. 临床肝胆病杂志. 2018(01): 106-111 . 本站查看
    8. 张津瑜，陈文显，沈华，王雁，张国雷，慎华平，吴万波，魏云海. 大鼠门静脉系统血栓形成模型的建立和观察. 中国普通外科杂志. 2018(06): 724-731 .
    9. 邢文立，李谦. 重症监护病房肝病患者的血栓预防与出血控制. 临床肝胆病杂志. 2018(10): 2237-2240 . 本站查看
    10. 李志州，向俊峰，周威，唐亮. 探讨门脉高压及外伤性脾破裂行脾切除术后血小板升高及门静脉血栓形成情况. 肝胆外科杂志. 2018(04): 280-282 .
    11. 王士浩，张宏伟. 肝硬化合并门静脉血栓形成危险因素的病例对照研究. 中国中西医结合消化杂志. 2017(11): 867-870 .

    Other cited types(12)

  • 加载中
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 24.9 %FULLTEXT: 24.9 %META: 68.8 %META: 68.8 %PDF: 6.4 %PDF: 6.4 %FULLTEXTMETAPDF
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 4.7 %其他: 4.7 %其他: 0.6 %其他: 0.6 %Bengaluru: 0.2 %Bengaluru: 0.2 %China: 0.7 %China: 0.7 %India: 0.2 %India: 0.2 %Japan: 0.1 %Japan: 0.1 %Kennedy Town: 0.2 %Kennedy Town: 0.2 %North Point: 0.2 %North Point: 0.2 %Seattle: 0.1 %Seattle: 0.1 %United States: 0.2 %United States: 0.2 %[]: 0.4 %[]: 0.4 %上海: 9.5 %上海: 9.5 %东莞: 0.6 %东莞: 0.6 %中卫: 0.1 %中卫: 0.1 %佛山: 0.2 %佛山: 0.2 %佳木斯: 0.1 %佳木斯: 0.1 %北京: 9.3 %北京: 9.3 %南京: 0.6 %南京: 0.6 %南宁: 0.1 %南宁: 0.1 %南阳: 0.1 %南阳: 0.1 %印度泰米尔纳德: 0.1 %印度泰米尔纳德: 0.1 %厦门: 0.1 %厦门: 0.1 %台北: 0.1 %台北: 0.1 %台州: 0.1 %台州: 0.1 %合肥: 0.3 %合肥: 0.3 %周口: 0.1 %周口: 0.1 %哈尔滨: 0.1 %哈尔滨: 0.1 %唐山: 0.1 %唐山: 0.1 %喀什: 0.2 %喀什: 0.2 %圣地亚哥: 0.1 %圣地亚哥: 0.1 %大连: 0.4 %大连: 0.4 %天津: 0.4 %天津: 0.4 %常德: 0.1 %常德: 0.1 %广州: 1.0 %广州: 1.0 %张家口: 1.4 %张家口: 1.4 %成都: 0.2 %成都: 0.2 %扬州: 0.3 %扬州: 0.3 %无锡: 0.2 %无锡: 0.2 %晋城: 0.2 %晋城: 0.2 %杭州: 0.5 %杭州: 0.5 %柳州: 0.1 %柳州: 0.1 %武汉: 0.3 %武汉: 0.3 %水牛城: 0.1 %水牛城: 0.1 %永州: 0.2 %永州: 0.2 %沈阳: 0.2 %沈阳: 0.2 %沈阳市和平区: 0.1 %沈阳市和平区: 0.1 %泰安: 0.2 %泰安: 0.2 %泰州: 0.3 %泰州: 0.3 %洛阳: 0.4 %洛阳: 0.4 %济南: 0.6 %济南: 0.6 %海得拉巴: 0.1 %海得拉巴: 0.1 %深圳: 0.5 %深圳: 0.5 %渭南: 0.1 %渭南: 0.1 %湘潭: 0.1 %湘潭: 0.1 %漯河: 0.1 %漯河: 0.1 %百色: 0.2 %百色: 0.2 %眉山: 0.1 %眉山: 0.1 %石嘴山: 0.1 %石嘴山: 0.1 %石家庄: 0.1 %石家庄: 0.1 %秦皇岛: 0.2 %秦皇岛: 0.2 %米兰: 0.1 %米兰: 0.1 %美国伊利诺斯芝加哥: 0.1 %美国伊利诺斯芝加哥: 0.1 %聊城市东昌府区: 0.1 %聊城市东昌府区: 0.1 %芒廷维尤: 38.2 %芒廷维尤: 38.2 %芝加哥: 0.3 %芝加哥: 0.3 %苏州: 0.1 %苏州: 0.1 %莫斯科: 0.6 %莫斯科: 0.6 %莱芜: 0.1 %莱芜: 0.1 %菏泽: 0.2 %菏泽: 0.2 %萍乡: 0.1 %萍乡: 0.1 %葵涌: 0.1 %葵涌: 0.1 %衢州: 0.1 %衢州: 0.1 %西宁: 14.2 %西宁: 14.2 %西安: 2.2 %西安: 2.2 %西安市新城区: 0.1 %西安市新城区: 0.1 %许昌: 0.1 %许昌: 0.1 %诺沃克: 0.1 %诺沃克: 0.1 %贵阳: 0.1 %贵阳: 0.1 %赤峰: 0.1 %赤峰: 0.1 %运城: 1.0 %运城: 1.0 %郑州: 0.2 %郑州: 0.2 %重庆: 0.1 %重庆: 0.1 %长春: 0.6 %长春: 0.6 %长沙: 2.2 %长沙: 2.2 %长治: 0.1 %长治: 0.1 %雅安: 1.0 %雅安: 1.0 %青岛: 0.4 %青岛: 0.4 %香港: 0.2 %香港: 0.2 %驻马店: 0.1 %驻马店: 0.1 %黄冈: 0.2 %黄冈: 0.2 %其他其他BengaluruChinaIndiaJapanKennedy TownNorth PointSeattleUnited States[]上海东莞中卫佛山佳木斯北京南京南宁南阳印度泰米尔纳德厦门台北台州合肥周口哈尔滨唐山喀什圣地亚哥大连天津常德广州张家口成都扬州无锡晋城杭州柳州武汉水牛城永州沈阳沈阳市和平区泰安泰州洛阳济南海得拉巴深圳渭南湘潭漯河百色眉山石嘴山石家庄秦皇岛米兰美国伊利诺斯芝加哥聊城市东昌府区芒廷维尤芝加哥苏州莫斯科莱芜菏泽萍乡葵涌衢州西宁西安西安市新城区许昌诺沃克贵阳赤峰运城郑州重庆长春长沙长治雅安青岛香港驻马店黄冈

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (899) PDF downloads(79) Cited by(23)
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[2462]YesterdayPV[4905]TodayIP[103]TodayPV[185]Online[46]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return